General description

PHAD^®-504 was designed as a synthetic structural analog of detoxified monophosphoryl lipid A (MPLA) derived from E. coli lipopolysaccharide (LPS). It is structurally similar to PHAD^®, differing only in the length of a single fatty acid chain. As expected, the activity of PHAD^®-504 is quite similar to that of PHAD^®, making the two products interchangeable as adjuvants in vaccine or immunotherapy formulations.

Legal Information

PHAD is a registered trademark of Avanti Polar Lipids, Inc.

Other Notes

For R&D use only. Not for drug, household, or other uses.

Packaging

2 mL Amber Glass Crimp Cap Vial (699810P-1mg)

2 mL Amber Glass Crimp Cap Vial (699810P-5mg)